Fig. 5.

. Impact of anti–CTLA-4 and anti-PD-1 immunotherapies in monotherapy or in combination on mice body weight A-C. Impact of anti–CTLA-4 and –PD-1 immunotherapies in monotherapy or in combination on CT26 (A) and 4T1 (B) mouse body weight. Anti-CTLA-4 and anti-PD-1 have been administered at days 6, 9, and 12 at respective doses of 100 and 200 µg i.p. per animal. Statistical differences between the groups were determined using by mixed-effects model (REML) (A) or two-ways ANOVA (B). Data represent mean and SD. n = 9–10 mice per group.